FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Optimizing Postneoadjuvant Treatment of Residual Breast Cancer With Adjuvant Bevacizumab Alone, With Metronomic or Standard-Dose Chemotherapy: A Combined Analysis of DFCI 05-055 and DFCI 09-134/TBCRC 012/ABCDE Clinical Trials. PMID 39890560 · Clin Breast Cancer · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| A Pilot Trial of Tongue Reconstruction Using the Chimeric Innervated Vastus Lateralis Muscle and Antero-Lateral Thigh Free Flap. PMID 39876833 · Head Neck · 2025-Jun This is a prospective, non-randomized controlled pilot study (not a randomized Phase III trial) evaluating a surgical reconstruction technique. The primary endpoints are complications and functional outcomes (e.g., swallowing, speech), not time-to-event efficacy endpoints like OS, PFS, or DFS. There is no drug intervention. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Description of STRIVE-ON Study Protocol: Safety and Tolerability of GTX-104 (Nimodipine Injection for IV Infusion) Compared with Oral Nimodipine in Patients Hospitalized for Aneurysmal Subarachnoid Hemorrhage (aSAH): A Prospective, Randomized, Phase III Trial (STRIVE-ON). PMID 39875683 · Neurocrit Care · 2025-Jun 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study. PMID 39846397 · J Eur Acad Dermatol Venereol · 2025-Jun The study fails the oncology requirement (alopecia areata is not a malignant neoplasm), lacks randomization, and does not have a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials. PMID 39844714 · Eur J Heart Fail · 2025-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Evaluating the impact of stratification on the power and cross-arm balance of randomized phase 2 clinical trials. PMID 39815460 · Clin Trials · 2025-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. PMID 39800653 · Clin Obes · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG). PMID 39779412 · Clin Colorectal Cancer · 2025-Jun 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Linzagolix rapidly reduces heavy menstrual bleeding in women with uterine fibroids: an analysis of the PRIMROSE 1 and 2 trials. PMID 39755138 · Fertil Steril · 2025-Jun The study investigates uterine fibroids (benign condition) and heavy menstrual bleeding, not a human malignant neoplasm. While it is a randomized Phase III trial with a drug intervention and a time-to-event endpoint, it is excluded because it is not an oncology study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| SOHO State of the Art Updates and Next Questions | Venetoclax + Obinutuzumab Therapy in Chronic Lymphocytic Leukemia. PMID 39732538 · Clin Lymphoma Myeloma Leuk · 2025-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Digital Pathology-based Artificial Intelligence Biomarker Validation in Metastatic Prostate Cancer. PMID 39665917 · Eur Urol Oncol · 2025-Jun The record is a secondary biomarker analysis of a Phase 3 randomized trial. It meets the criteria for oncology, human, randomized, phase 3, and time-to-event, but it is excluded because it is not a primary report of a drug-containing intervention. The intervention in the original trial was a drug, but this specific report is a biomarker analysis without reporting on the drug intervention itself. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Remote Symptom Monitoring of Patients With Advanced Lung Cancer (The ProWide Study): A Randomized Controlled Trial. PMID 39657078 · JCO Oncol Pract · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Association Between age or Duration of Diagnosis in Obstructive Hypertrophic Cardiomyopathy and Response to Mavacamten Treatment: Exploratory Analysis of the EXPLORER-HCM Trial. PMID 39653325 · J Card Fail · 2025-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Treatment With Oral or Inhaled Treprostinil in Patients With Pulmonary Arterial Hypertension and Cardiovascular Comorbidities. PMID 39622469 · Chest · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Maribavir for refractory cytomegalovirus infection (with or without resistance) in solid organ transplant recipients: Subgroup analysis of the phase 3 randomized SOLSTICE study. PMID 39613120 · J Heart Lung Transplant · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Subcutaneous Abatacept Plus Standard Treatment for Active Idiopathic Inflammatory Myopathy: Phase 3 Randomized Controlled Trial. PMID 39609094 · Arthritis Rheumatol · 2025-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Reducing Overtreatment of Prostate Cancer Patients: Revisiting the European Association of Urology Pretreatment Risk Group Classification Using Long-term Follow-up Data from the European Randomized Study of Screening for Prostate Cancer Rotterdam. PMID 39603883 · Eur Urol Oncol · 2025-Jun Study is a randomized analysis of risk stratification from a screening trial, not a randomized trial of a drug-containing intervention for cancer treatment. It evaluates risk classification systems, not a drug therapy, and does not meet the drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Resolution of Angiographic Macular Leakage with Faricimab versus Aflibercept in Patients with Diabetic Macular Edema in YOSEMITE/RHINE. PMID 39580145 · Ophthalmol Retina · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease. PMID 39544897 · J Scleroderma Relat Disord · 2025-Jun 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial. PMID 39537438 · Eur Urol · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Correlation of Body Mass Index with Overall Survival Among Patients with Metastatic Hormone-sensitive Prostate Cancer: Analysis of Patient-level Data from SWOG-1216. PMID 39521639 · Eur Urol Oncol · 2025-Jun 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Treatment of early-onset fetal growth restriction with low molecular weight heparin does not prolong gestation: a randomized clinical trial. PMID 39521297 · Am J Obstet Gynecol · 2025-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Endoscopic background mucosal resurfacing to prevent metachronous recurrence of superficial esophageal squamous cell cancer after curative endoscopic submucosal dissection: randomized pilot study with 5-year follow-up (with video). PMID 39521094 · Gastrointest Endosc · 2025-Jun 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Pitolisant 40 mg for excessive daytime sleepiness in obstructive sleep apnea patients treated or not by CPAP: Randomised phase 3 study. PMID 39377364 · J Sleep Res · 2025-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Remote electrical neuromodulation to treat children and adolescents with migraine in the emergency department: A randomized double-dummy pilot trial. PMID 39290050 · Headache · 2025-Jun 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Effects of high-intensity interval training on cardiometabolic biomarkers in patients with prostate cancer undergoing active surveillance: a randomized controlled trial. PMID 39009705 · Prostate Cancer Prostatic Dis · 2025-Jun The study is a randomized trial in oncology patients, but it examines an exercise intervention (non-drug) and reports cardiometabolic biomarker outcomes, not a time-to-event efficacy endpoint (e.g., OS, PFS, DFS). It lacks a drug-containing intervention and a primary/key secondary time-to-event endpoint, which are required for inclusion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Dexamethasone for 12 weeks for reducing fatigue in patients receiving palliative chemotherapy: A Phase 3, Placebo-Controlled, Randomized Controlled Trial. PMID 40739403 · Support Care Cancer · 2025-Jul-31 The trial meets criteria for oncology, human, randomized, phase III, drug intervention, and original result. However, the primary endpoint is cancer-associated fatigue measured by symptom scales at fixed time points, not a time-to-event endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or a Kaplan-Meier/HR analysis. Therefore, it does not meet the key requirement for a time-to-event efficacy endpoint. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| rhPTH(1-84) for hypoparathyroidism: a randomized study of patient-reported outcomes. PMID 40711996 · Eur J Endocrinol · 2025-Jul-31 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma. PMID 40459097 · N Engl J Med · 2025-Jul-31 The trial is an eligible oncology Phase III randomized drug trial with original results, but the primary and key secondary endpoints are based on measurable residual disease (MRD) status, which is a categorical, non-time-to-event outcome. No time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or survival analysis (e.g., Kaplan-Meier, HR) is reported as a primary or key secondary result. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Long-term prognosis of intracorporeal versus extracorporeal anastomosis in stage II/III colorectal cancer (INEX study): study protocol for a multicenter randomized controlled trial in Japan. PMID 40739197 · BMC Cancer · 2025-Jul-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Adebrelimab plus capecitabine versus capecitabine monotherapy for adjuvant treatment of high-risk resected cholangiocarcinoma (ACHIEVE): protocol for a phase II, multicentre, randomised controlled trial. PMID 40738506 · BMJ Open Gastroenterol · 2025-Jul-30 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| User-Centered Refinement of a Digital Tool for Tuberculosis Treatment Support: Iterative Mixed Methods Study. PMID 40737522 · J Med Internet Res · 2025-Jul-30 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Mobile Health Technology for Personalized Tobacco Cessation Support Among Cancer Survivors and Caregivers in Laos (Project SurvLaos): Protocol for a Pilot Randomized Controlled Trial. PMID 40736921 · JMIR Res Protoc · 2025-Jul-30 This is a protocol for a pilot randomized controlled trial evaluating a mobile health smoking cessation program for cancer survivors and caregivers. It is not a Phase III drug trial, does not have a time-to-event efficacy endpoint, and lacks completed results. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Quality of life following ileostomy takedown: single-centre, retrospective clinical trial-does closure time matter? PMID 40736758 · Tech Coloproctol · 2025-Jul-30 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Designing, validation and evaluation of an mHealth app for prenatal health promotion based on the unified theory of acceptance and use of technology: A mixed methods study protocol. PMID 40730798 · Sci Rep · 2025-Jul-29 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Nutritional status and impact on outcomes of patients with locally advanced head and neck squamous cell carcinoma treated with concurrent chemoradiotherapy: a pre-planned secondary analysis of a phase 3 randomized controlled trial. PMID 40717193 · J Egypt Natl Canc Inst · 2025-Jul-28 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Efficacy of the first-line immune checkpoint inhibitor plus chemotherapy for gastroesophageal cancer: A meta-analysis of phase III trials including unreported PD-L1 subgroups. PMID 40239914 · Cancer Lett · 2025-Jul-28 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Identifying and assessing the capacity and experience of trial sites in low- and middle-income countries for high-quality randomised drug trials in maternal and perinatal health. PMID 40716797 · BMJ Glob Health · 2025-Jul-27 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trials. PMID 40684778 · Lancet · 2025-Jul-26 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Beneficial value of [18F]FDG PET/CT in the follow-up of patients with stage III non-small cell lung cancer (NVALT31-PET study): study protocol of a multicentre randomised controlled trial. PMID 40713037 · BMJ Open · 2025-Jul-25 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Patient-directed behavioral-physical interventions to alleviate acute hiccups associated with chemotherapy: a prospective randomized controlled trial. PMID 40711569 · Support Care Cancer · 2025-Jul-25 The study is a randomized trial in oncology patients, but it fails eligibility because: 1) the intervention is non-pharmacological (behavioral-physical), not a drug-containing intervention, 2) the primary endpoint is not a time-to-event efficacy endpoint relevant to oncologic treatment (like OS/PFS), and 3) it is not established as a Phase III or definitive trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). PMID 40580811 · Eur J Cancer · 2025-Jul-25 The record describes a prospective cohort study (a prespecified study within a phase III trial) assessing genomic profiling agreement between primary tumors and lymph node metastases. It does not report primary efficacy results (e.g., OS, PFS, DFS) or any time-to-event endpoint from the randomized trial. It is an ancillary/translational study, not the original formal result report of a randomized trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Bempedoic Acid in Japanese Patients With Hypercholesterolemia - A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study (the CLEAR-J Trial). PMID 40159243 · Circ J · 2025-Jul-25 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| REPAIR_GETUG P16 relapse in previously irradiated prostate bed: a phase I/II study of stereotactic ablative reirradiation potentiated by a metformine study protocol. PMID 40707156 · BMJ Open · 2025-Jul-24 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Transporting trial results to synthetic real-world populations in order to estimate real-world effectiveness of newly marketed medicines. PMID 40707153 · BMJ Open · 2025-Jul-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Ivermectin to Control Malaria - A Cluster-Randomized Trial. PMID 40700688 · N Engl J Med · 2025-Jul-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy. PMID 40548694 · N Engl J Med · 2025-Jul-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III clinical trial to assess the efficacy and safety of Yuping Tongqiao tablets in the treatment of persistent allergic rhinitis. PMID 40473149 · J Ethnopharmacol · 2025-Jul-24 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial. PMID 40702551 · J Transl Med · 2025-Jul-23 The record describes a randomized, multicenter trial with a drug-containing intervention and primary time-to-event endpoints (OS, PFS), but the abstract and metadata do not explicitly state the trial phase. The deterministic review flagged phase evidence as unclear. Without explicit phase confirmation, eligibility cannot be established. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Telehealth and Online Cognitive Behavioral Therapy-Based Treatments for High-Impact Chronic Pain: A Randomized Clinical Trial. PMID 40699570 · JAMA · 2025-Jul-23 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |